Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Amlodipine Used as add-on Therapy in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil 20 mg Monotherapy

NCT00220220 is registered in ClinicalTrials.gov with Sankyo Pharma Gmbh as lead sponsor.

NCT NCT00220220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00220220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Amlodipine Used as add-on Therapy in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil 20 mg Monotherapy
Lead sponsor
Sankyo Pharma Gmbh
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2005
Completion date
April 30, 2007
Enrollment
429 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

essential hypertension